Summit Health Announces Internalization of GTC’s State-of-The-Art Next Gen Sequencing DNA & RNA Profiling Tests for Tissue and Liquid Biopsy of Solid Tumors and Hematologic
GTC Expands Cancer Tests to Europe via Partnership By Yuika Yoshida April 7, 2025 Genomic Testing Cooperative (GTC) is expanding into the European market by partnering with
Lake Forest, CA – April 8, 2025 – Genomic Testing Cooperative (GTC) today announced it received UKCA marks for its Hematology Profile Plus, Solid Tumor
Cologne, Germany and Lake Forest, CA. USA, March 18, 2025 – Labor Dr. Wisplinghoff one of Germanys largest and most renowned medical laboratories and Genomic
Lake Forest, CA – November 13, 2024 – Genomic Testing Cooperative (GTC), a leader in advanced genomic testing, announced the launch of GTC Interpret, a
Manchester, NH – June 25, 2024 – BioAI, an emerging biotech company applying multimodal artificial intelligence (AI) to novel biomarker discovery, development, and diagnostics, announced a strategic collaboration with Genomic Testing Cooperative (GTC), a leading provider of molecular diagnostics for solid tumors and hematologic malignancies. This collaboration leverages the AI capabilities of both companies to deliver innovative solutions that meet the needs of pharmaceutical companies and clinicians, ultimately enhancing patient care in oncology. GTC will become an early technology access member of BioAI’s global ecosystem of clinical laboratories.
CorePath Laboratories is partnering with Genomic Testing Cooperative (GTC) to enhance its next-generation sequencing (NGS) capabilities for cancer diagnostics. This collaboration combines targeted DNA and RNA profiling with other pathology testing methods, providing comprehensive evaluations of patient samples. Additionally, liquid biopsy capabilities offer a non-invasive way to monitor therapy and detect relapse.
Irvine, California– May 31, 2023 – Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the 2023 American Society of Clinical Oncology
Baltimore, MD and Irvine, CA, April 13, 2023, Sysmex Inostics Inc., a subsidiary of Japan’s Sysmex Corporation and Baltimore-based biotechnology firm, and Genomic Testing Cooperative
Demonstrating Reliability of Targeted Transcriptomic Profiling in Predicting Levels of HER2, ER, PD-L1 and Other Immunohistochemistry-based Biomarkers when Combined with Artificial Intelligence Irvine, California– April
